MedPath

CytoMed Therapeutics Initiates Phase I Trial of CTM-ONC in Solid Tumors

• CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC in patients with advanced solid tumors. • The trial utilizes CytoMed's patented donor-derived allogeneic cell therapy platform to enhance safety and efficacy. • CTM-ONC targets tumors expressing high levels of certain activating ligands, aiming to improve patient outcomes. • This first-in-human study marks a significant step for CytoMed in developing innovative cancer immunotherapies.

CytoMed Therapeutics has announced the initiation of its first-in-human Phase I ANGELICA clinical trial, evaluating the safety and efficacy of CTM-ONC in patients with advanced solid tumors. This trial marks a significant milestone for the company, utilizing its patented donor-derived allogeneic cell therapy platform.
The ANGELICA trial is designed to assess the safety, tolerability, and preliminary efficacy of CTM-ONC, an innovative immunotherapy product. CTM-ONC is designed to target and eliminate cancer cells expressing high levels of specific activating ligands. The study aims to enroll patients with advanced solid tumors who have exhausted standard treatment options.

Trial Design and Objectives

The Phase I trial is an open-label, dose-escalation study. The primary objective is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of CTM-ONC. Secondary objectives include assessing the preliminary efficacy of CTM-ONC based on objective response rate (ORR), disease control rate (DCR), and duration of response (DoR), as well as evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the therapy.

CTM-ONC: A Novel Immunotherapy Approach

CTM-ONC leverages CytoMed's proprietary allogeneic cell therapy platform, which is designed to enhance the safety and efficacy of cell-based immunotherapies. By utilizing donor-derived cells, CTM-ONC aims to overcome some of the limitations associated with autologous cell therapies, such as manufacturing challenges and patient-specific variability.
The therapy is engineered to target tumors expressing high levels of specific activating ligands, which are often upregulated in various solid tumors. This targeted approach aims to selectively eliminate cancer cells while sparing healthy tissues, potentially reducing off-target toxicities.

The Need for Innovative Cancer Therapies

Advanced solid tumors remain a significant challenge in oncology, with many patients experiencing disease progression despite available treatments. There is a critical need for innovative therapies that can improve outcomes and extend survival for these patients. CTM-ONC represents a promising new approach to cancer immunotherapy, with the potential to address this unmet medical need.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Biomea Fusion Announces Topline Results from Phase II COVALENT-111 Trial

Biomea Fusion is set to release topline results from its Phase II COVALENT-111 clinical trial, which evaluates a novel covalent menin inhibitor.
The trial focuses on patients with relapsed or refractory acute myeloid leukemia (AML), a challenging-to-treat blood cancer.

Lyell Immunopharma's IMPT-314 Shows Promise in CAR-T Naive Large B-Cell Lymphoma Patients

Lyell Immunopharma announced encouraging initial clinical data for IMPT-314 in patients with large B-cell lymphoma who have not previously received CAR-T therapy.
IMPT-314, a ROR1-targeting CAR-T cell therapy, demonstrated notable anti-tumor activity in early-stage clinical trials, offering a potential new treatment option.

Delta-Fly Pharma's DFP-14323 Phase III Trial Progresses with Afatinib Recommendation

Delta-Fly Pharma's Phase III trial of DFP-14323 in combination with Afatinib for NSCLC is ongoing, targeting EGFR mutation-positive uncommon mutations.
Afatinib received a strong recommendation as a first-line treatment for EGFR mutation-positive NSCLC in Japan's Lung Cancer Treatment Guidelines 2024.

Puma Biotechnology Initiates Phase II Trial of Alisertib in HR+/HER2- Breast Cancer

Puma Biotechnology has commenced the ALISCA™-Breast1 Phase II trial to evaluate alisertib in hormone receptor-positive, HER2-negative advanced breast cancer.
The trial will assess the efficacy and safety of alisertib in patients who have progressed on prior CDK4/6 inhibitor therapy.

Replimune Presents Promising Data from IGNYTE Trial of RP1 in Solid Tumors

Replimune's IGNYTE trial showcases the potential of RP1, a novel oncolytic virus, in treating various solid tumors, offering hope for patients with limited options.
The late-breaking abstract highlights encouraging response rates and tolerability of RP1, administered alone or in combination with other therapies, warranting further investigation.

NEJM Highlights PredicineCARE™ Liquid Biopsy Assay in Roche's Phase III Trial

Roche's Phase III trial utilizes PredicineCARE™ liquid biopsy assay for patient selection and monitoring, showcasing its pivotal role in clinical research.
The assay's ability to detect actionable genomic alterations in plasma ctDNA guides targeted therapy decisions, potentially improving patient outcomes.

FDA Approves Abionic's CAPSULE PSP for Rapid Sepsis Detection

Abionic's CAPSULE PSP, a point-of-care diagnostic, has received FDA approval for early sepsis detection, enabling quicker clinical decision-making.
The device measures Pancreatic Stone Protein (PSP) levels, a biomarker that rises rapidly in response to bacterial infections leading to sepsis.

Celldex's Barzolvolimab Meets All Primary and Secondary Endpoints in Clinical Trial

Celldex Therapeutics announced that barzolvolimab met all primary and secondary endpoints with high statistical significance in a recent clinical trial.
Barzolvolimab is a novel monoclonal antibody designed to bind to and inhibit the KIT receptor, potentially treating various mast cell-driven diseases.

CytoMed Therapeutics' ANGELICA Trial Receives Approval for Phase I Study in Advanced Cancers

CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers.
The ANGELICA trial uses gamma delta T cells from healthy donors, potentially improving CAR-T cell quality and reducing production costs.

FDA Grants Rare Pediatric Disease Designation to Modalis Therapeutics' MDL-101 for Genetic Disorder Treatment

Modalis Therapeutics receives Rare Pediatric Disease Designation from the FDA for MDL-101, targeting a severe genetic disorder.
MDL-101 is designed to address the underlying genetic cause of the disease, offering a potential new treatment avenue.

Reference News

[1]
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor
bakersfield.com · Oct 7, 2024

A form includes dropdowns for selecting a state, zip code, and country, with California preselected and the United State...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy